CA2991777A1 - Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor - Google Patents

Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor Download PDF

Info

Publication number
CA2991777A1
CA2991777A1 CA2991777A CA2991777A CA2991777A1 CA 2991777 A1 CA2991777 A1 CA 2991777A1 CA 2991777 A CA2991777 A CA 2991777A CA 2991777 A CA2991777 A CA 2991777A CA 2991777 A1 CA2991777 A1 CA 2991777A1
Authority
CA
Canada
Prior art keywords
cancer
mek
hsf1
cells
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2991777A
Other languages
English (en)
French (fr)
Inventor
Chengkai DAI
Zijian Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jackson Laboratory
Original Assignee
Jackson Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson Laboratory filed Critical Jackson Laboratory
Publication of CA2991777A1 publication Critical patent/CA2991777A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2991777A 2015-07-09 2015-08-11 Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor Abandoned CA2991777A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190563P 2015-07-09 2015-07-09
US62/190,563 2015-07-09
PCT/US2015/044662 WO2017007495A1 (en) 2015-07-09 2015-08-11 Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor

Publications (1)

Publication Number Publication Date
CA2991777A1 true CA2991777A1 (en) 2017-01-12

Family

ID=57685946

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2991777A Abandoned CA2991777A1 (en) 2015-07-09 2015-08-11 Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor

Country Status (6)

Country Link
US (1) US20180369203A1 (enExample)
JP (1) JP2018520164A (enExample)
KR (1) KR20180021198A (enExample)
AU (1) AU2015401587A1 (enExample)
CA (1) CA2991777A1 (enExample)
WO (1) WO2017007495A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4087840A4 (en) 2020-01-10 2024-01-10 Immuneering Corporation Mek inhibitors and therapeutic uses thereof
US20250099467A1 (en) * 2022-01-25 2025-03-27 Verastem, Inc. Combination therapy for treating abnormal cell growth
CN115120731A (zh) * 2022-07-12 2022-09-30 四川大学华西医院 一种靶向蛋白酶体治疗乳腺癌的药物应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370568B1 (en) * 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US20150071918A1 (en) * 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物

Also Published As

Publication number Publication date
JP2018520164A (ja) 2018-07-26
WO2017007495A1 (en) 2017-01-12
KR20180021198A (ko) 2018-02-28
AU2015401587A1 (en) 2018-02-01
US20180369203A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
Tang et al. MEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1
Gallo et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
Marchi et al. Akt‐mediated phosphorylation of MICU1 regulates mitochondrial Ca2+ levels and tumor growth
Zhang et al. Curcumin induces endoplasmic reticulum stress-associated apoptosis in human papillary thyroid carcinoma BCPAP cells via disruption of intracellular calcium homeostasis
Cheng et al. YM155 down‐regulates survivin and XIAP, modulates autophagy and induces autophagy‐dependent DNA damage in breast cancer cells
Martínez-Carreres et al. CDK4 regulates lysosomal function and mTORC1 activation to promote cancer cell survival
Liu et al. Cdk5 links with DNA damage response and cancer
Xu et al. IU1 suppresses proliferation of cervical cancer cells through MDM2 degradation
Lu et al. BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells
Chen et al. Bmi‐1‐RING1B prevents GATA4‐dependent senescence‐associated pathological cardiac hypertrophy by promoting autophagic degradation of GATA4
Zhang et al. Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy
Lone et al. Non-POU domain-containing octomer-binding (NONO) protein expression and stability promotes the tumorigenicity and activation of Akt/MAPK/β-catenin pathways in human breast cancer cells
Xiao et al. USP39-mediated deubiquitination of Cyclin B1 promotes tumor cell proliferation and glioma progression
US20220280590A1 (en) Use of inhibitors of yap and sox2 for the treatment of cancer
Xie et al. Centrosomal localization of RXRα promotes PLK1 activation and mitotic progression and constitutes a tumor vulnerability
US20180369203A1 (en) Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor
Kim et al. TBK1 is a signaling hub in coordinating stress-adaptive mechanisms in head and neck cancer progression
Zhang et al. CaMKII suppresses proteotoxicity by phosphorylating BAG3 in response to proteasomal dysfunction
Wang et al. Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin β1 localization
Albihn et al. Camptothecin‐induced apoptosis is enhanced by Myc and involves PKCdelta signaling
WO2012121662A1 (en) Novel pharmaceutical combinations and methods for treating cancer
Hattori et al. Induction of synergistic non-apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells
Wang et al. Inhibition of atypical protein kinase Cι induces apoptosis through autophagic degradation of β‐catenin in esophageal cancer cells
Luo et al. Dcf1 induces glioblastoma cells apoptosis by blocking autophagy
Mancini et al. SETD2 loss of function is a recurrent event in advanced‐phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid Leukemia

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123